|
Synonyms: E-01AJ | E-10030 | E01AJ | E10030 | Fovista® | X-01E | X01E
Compound class:
Nucleic acid
Comment: Pegpleranib (E10030) is a 32-mer pegylated DNA aptamer that selectively binds to PDGF-BB and PDGF-AB homo- and hetero-dimers. It prevents PDGF binding to its cognate PDGF receptors. Blocking receptor activation leads to the death of capillary pericytes. This mechanism was investigated as a disruptor of vessel formation in neovascular age related macular degeneration. Pegpleranib is formulated as a sodium adduct for therapeutic administration (see DBSALT002614).
|
Classification  |
|
| Compound class | Nucleic acid |
| Compound subclass | Aptamer |
| Target | Platelet-derived growth factor subunit B |
| International Nonproprietary Names |
|
| INN number | INN |
| 10044 | pegpleranib |
| Synonyms |
| E-01AJ | E-10030 | E01AJ | E10030 | Fovista® | X-01E | X01E |
| Database Links |
|
| CAS Registry No. | 1449390-73-1 (source: WHO INN record) |
| ChEMBL Ligand | CHEMBL3301576 |
| DrugBank Ligand | DBSALT002614 |
| GtoPdb PubChem SID | 500839942 |
| Search PubMed clinical trials | pegpleranib |
| Search PubMed titles | pegpleranib |
| Search PubMed titles/abstracts | pegpleranib |
